Results 121 to 130 of about 457,403 (331)

Molecular mechanism of Huaihuasan in treatment of ulcerative colitis based on network pharmacology and molecular docking

Phytomedicine Plus, 2021
Background: Huaihuasan (HHS) is a Traditional Chinese Medicine formula for ulcerative colitis (UC). However, the pharmacology and molecular mechanism of HHS on ulcerative colitis still unclear.
Yi Wu, Xiaokun Yang, Guiwei Li, Xinqiao Liu   +3 more
doaj  

Anatomical Region of the Colon as an Influencing Factor for Ulcerative Colitis Development

Central Asian Journal of Medical Sciences, 2016
Objectives: To determine if the anatomical location and extent of ulcerative inflammation influences the primary development of ulcerative colitis by defining the primary starting locations of ulcerative inflammation processes and determining the ...
Enkhbaatar Tseden, Adilzaya Damdinsuren, Davaadorj Duger   +2 more
doaj   +1 more source

Protective Effect of Curcumin on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Obese Mice

Korean Journal of Clinical Laboratory Science, 2022
Ulcerative colitis is a disease that causes inflammation in the mucosal or submucosal layer of the colon. Previous studies have reported that obesity increases the prevalence of ulcerative colitis and aggravates the progression.
Ho Park
doaj   +1 more source

Heme oxygenase-1 as a modulator of intestinal inflammation development and progression [PDF]

, 2018
Indexación: Scopus.Heme Oxygenase 1 (HMOX1) is an enzyme that catalyzes the reaction that degrades the heme group contained in several important proteins, such as hemoglobin, myoglobin, and cytochrome p450.
Alexis M. Kalergis, Alexis M. Kalergis, Bárbara M. Schultz, Claudia A. Riedel, Geraldyne A. Salazar, Irenice Coronado-Arrázola, Loni Berkowitz, Loni Berkowitz, Manuel M. Álvarez-Lobos, Manuel M. Álvarez-Lobos, Omar P. Vallejos, Susan M. Bueno, Valentina P. Sebastián   +12 more
core   +2 more sources

Microbial Biosensor for Sensing and Treatment of Intestinal Inflammation

Advanced Science, EarlyView.
The engineered calprotectin biosensor detects gut inflammation, processes the signal through genetic regulation, and responds by expressing the reporter sfGFP and the therapeutic protein secIL10. This dual functionality enables the engineered biosensor not only to sense but also to mitigate gut inflammation, highlighting its potential for disease ...
Duolong Zhu, Jeffrey Galley, Jason Pizzini, Elena Musteata, Martin V. Douglas, Walter J. Chazin, Eric P. Skaar, Jeffrey J. Tabor, Robert A. Britton   +8 more
wiley   +1 more source

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab [PDF]

, 2019
Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC ...
Diogo Branquinho, Fernando Magro, Francisco Portela, Fátima Carneiro, George Philip, Gisbert JP, Helena Tavares de Sousa, Isabel Redondo, Jaime Ramos, Joana Afonso, Joanne Lopes, Kim DB, Luís Correia, Magro F, Marco Silva, Marta Patita, Marília Cravo, Patrícia Machado, Paula Lago, Paulo Caldeira, Rosa Coelho, Samuel Fernandes, Susana Lopes   +22 more
core   +3 more sources

Probiotic‐Enhanced Porous Bio‐Hybrids with Inflammatory Targeting, ROS Scavenging, and Long‐Term Drug Release for Ulcerative Colitis Treatment

Advanced Science, EarlyView.
Probiotic‐enhanced porous bio‐hybrids (E‐xPAM@ASA), developed by coupling the drug‐loaded hairy microporous nanospheres xPAM@ASA with probiotic EcN, integrate inflammatory‐targeting, ROS scavenging, and long‐term release of 5‐ASA to improve inflammation and regulate microbiota structure in the DSS‐induced colitis model, providing an advanced strategy ...
Luna Quan, Yang Ouyang, Weiwen Liang, Zixin Chen, Dongtian Miao, Bingna Zheng, Dingcai Wu, Rongkang Huang   +7 more
wiley   +1 more source

Restorative proctocolectomy with ileal pouch reservoir in ulcerative colitis : the first series from Malta [PDF]

, 1991
Seventy five to eighty percent of patients with ulcerative colitis are more or less satisfactorily treated medically. Surgery cures the disease, but because proper surgical therapy has until recently necessitated a permanent ileostomy, physicians and ...
Gatt, Dennis
core  

Assessment of Circulating MicroRNAs for the Diagnosis and Disease Activity Evaluation in Patients with Ulcerative Colitis by Using the Nanostring Technology [PDF]

, 2015
Background: Clinical decision and patient care management in inflammatory bowel diseases is largely based on the assessment of clinical symptoms, while the biomarkers currently in use poorly reflect the actual disease activity.
Alexandra Touroutoglou, Angelos Oikonomopoulos, Baltimore, Baumgart, Cho, Christos Polytarchou, CramaBohbouth, Creemers, Daniel W. Hommes, Dimitrios Iliopoulos, Georgios Koukos, Guo, Hatziapostolou, Iskandar, Kappelman, Kosaka, Kumar, Lewis, Linskens, Loftus, Mitchell, Pepys, Saverymuttu, Schoepfer, Schroeder, Schwarzenbach, Solem, Solem, Swapna Mahurkar, van Rooij, Wang, Xavier   +31 more
core   +1 more source

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

New England Journal of Medicine, 2013
BACKGROUND Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients ...
B. Feagan, P. Rutgeerts, B. Sands, S. Hanauer, J. Colombel, W. Sandborn, G. Van Assche, J. Axler, Hyo-Jong Kim, S. Danese, I. Fox, C. Milch, S. Sankoh, T. Wyant, Jing Xu, A. Parikh   +15 more
semanticscholar   +1 more source